The use of ketamine in treating mood disorders is still considered to be an “off-label” use. This means that ketamine was created as an anesthetic/analgesic for surgical procedures. The fact that it effectively treats depression and other mood disorders is irrelevant until the drug is reclassified as an antidepressant. So, until ketamine is reclassified by the FDA, insurance companies are not obliged to reimburse for ketamine infusion therapy. Patients can try to get reimbursed on their own for treatments of mood disorders or pain treatments.